Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 27;4(9):e387. doi: 10.1097/TXD.0000000000000827

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

MSC treatment resulted in significant decreases in DSA as soon as 1 week after treatment initiation. We tested DSA levels at baseline, day 14, day 21, and day 28 in sensitized and treatment groups (T2 and T8, respectively). In the treatment group (T8), the first MSC infusion was delivered on day 14. One week later (day 21), a significant (P < 0.05) drop in IgG1 DSA was evident (A). IgG2a and IgG2c isotypes had significant (P < 0.05) decreases by 2 weeks after initiation of MSC therapy (B, C).